Correlation of serum Nesfatin 1 level with metabolic and clinical parameters in Indian women with and without polycystic ovarian syndrome

Faeza Fatima; Pikee Saxena; Anju Jain

doi:10.18203/2320-1770.ijrcog20230128

Authors

Faeza Fatima Department of Obstetrics and Gynecology, Lady Hardinge Medical College and SSKH, New Delhi, India
Pikee Saxena Department of Obstetrics and Gynecology, Lady Hardinge Medical College and SSKH, New Delhi, India
Anju Jain Department of Biochemistry, Lady Hardinge Medical College and SSKH, New Delhi, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20230128

Keywords:

Polycystic ovarian syndrome, Nesfatin 1, Energy homeostasis, New marker

Abstract

Background: Objective of the study was to compare serum Nesfatin 1 levels in Indian women with and without polycystic ovarian syndrome (PCOS) and to evaluate the association of serum Nesfatin 1 with metabolic and clinical parameters.

Methods: 40 PCOS and 40 age and body mass index (BMI) matched non PCOS controls were enrolled. Comparison of hormonal (serum Nesfatin 1, anti-Mullerian hormone (AMH), follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin, testosterone, and estadiol) metabolic (blood pressure, fasting and post prandial blood glucose and insulin, HOMA-IR) and clinical (acne, acanthosis nigricans and hirsutism) parameters was done between two groups. Student’s t test, Mann Whitney test, Pearson’s correlation test was used. P value of <0.05 was considered statistically significant.

Results: There was a significant difference in levels of serum Nesfatin 1 in PCOS subjects and controls (8.6 ng/ml versus 0.75 ng/ml, p<0.01). Positive correlation was present between serum nesfatin 1 level and post prandial plasma glucose (r=0.009; p<0.009). A positive correlation was also present between serum Nesfatin 1 levels and AMH (r=0.512; p<0.01). No correlation was found between serum Nesfatin 1 and other endocrine, cardiovascular and metabolic parameters. Serum LH levels, LH/FSH ratio, post prandial plasma glucose and post prandial insulin were significantly higher (p<0.05) in PCOS subjects compared to controls.

Conclusions: Nesfatin 1 levels were ten times higher in PCOS subjects compared to controls irrespective of age and BMI. A positive correlation was observed between serum Nesfatin 1 and post prandial plasma glucose levels which indicates Nesfatin 1 may be a reliable marker of PCOS suggesting energy homeostasis imbalance in these women.

Metrics

Metrics Loading ...

References

The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.

Yamada M, Horiguchi K, Umezawa R. Troglitazone, a ligand of peroxisome proliferator-activated receptor-{gamma}, stabilizes NUCB2 (Nesfatin) mrna by activating the ERK1/2 pathway: isolation and characterization of the human NUCB2 gene. Endocrinology. 2010;151(6): 2494-503.

Bonnet MS, Pecchi E. Central nesfatin-1-expressing neurons are sensitive to peripheral inflammatory stimulus. J Neuroinflammation. 2009;6:27.

Dore R, Levata L, Lehnert H, Schulz C. Nesfatin-1: Functions and physiology of a novel regulatory peptide. J Endocrinol. 2017;232:R45-65.

Sahin FK, Sahin SB, Ural UM, Cure MC, Senturk S, Tekin YB, Balik G, Cure E, Yuce S, Kirbas A. Nesfatin-1 and vitamin D levels may be associated with systolic and diastolic blood pressure values and hearth rate in polycystic ovary syndrome. Bosn J Basic Med Sci. 2015;15(3):57-63.

Mierzyński R, Poniedziałek-Czajkowska E, Dłuski D, Patro-Małysza J, Kimber-Trojnar Ż, Majsterek M, Leszczyńska-Gorzelak B. Nesfatin-1 and Vaspin as Potential Novel Biomarkers for the Prediction and Early Diagnosis of Gestational Diabetes Mellitus. Int J Mol Sci. 2019;20(1):159.

Öztürk Özkan G. Effects of Nesfatin-1 on Food Intake and Hyperglycemia. J Am Coll Nutr. 2020;39(4):345-51.

Ademoglu EN, Gorar S, Carlıoglu A, Yazıcı H, Dellal FD, Berberoglu Z, et al. Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome. J Endocrinol Invest. 2014;37(8):715719.

Catak Z, Yavuzkir S, Kocdemir E, Ugur K, Yardim M, Sahin İ, Agirbas EP, Aydin S. NUCB2/Nesfatin-1 in the Blood and Follicular Fluid in Patients with Polycystic Ovary Syndrome and Poor Ovarian Response. J Reprod Infertil. 2019;20(4):225-30.

Saxena P, Singh S, Bhattacharjee J. Endocrine and Metabolic Profile of Different Phenotypes of Polycystic Ovarian Syndrome. J Obstet Gynaecol India. 2016;66(1):560-6.

Kar S. Anthropometric, clinical & metabolic comparison of four Rotterdam PCOS phenotypes—a prospective study. J Hum Reprod Sci. 2013;6(3):194-200.

Binnetoğlu E, Erbağ G, Gencer M, Turkön H, Mehmetaşik, Güneş H, Sen H, Ahmetvural, Kubilayukin, Plasma levels of nesfatin-1 in patients with polycystic ovary syndrome. Acta Medica Mediterranea. 2014;30:201-4.

Deniz R, Gurates B, Aydin S. Nesfatin-1 and other hormone alterations in polycystic ovary syndrome. Endocrine. 2012;42(33):694-9.